Abstract
Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Current Pharmaceutical Biotechnology
Title:Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Volume: 15 Issue: 11
Author(s): Dai Mizuno, Hironari Koyama, Susumu Ohkawara, Yutaka Sadakane and Masahiro Kawahara
Affiliation:
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Abstract: Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Export Options
About this article
Cite this article as:
Mizuno Dai, Koyama Hironari, Ohkawara Susumu, Sadakane Yutaka and Kawahara Masahiro, Involvement of Trace Elements in the Pathogenesis of Prion Diseases, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141103020625
DOI https://dx.doi.org/10.2174/1389201015666141103020625 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk
Protein & Peptide Letters Boron Nitride Nanotubes: A Novel Vector for Targeted Magnetic Drug Delivery
Current Nanoscience Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications
Current Medicinal Chemistry Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo
Clinical Cancer Drugs Click Chemistry, A Potent Tool in Medicinal Sciences
Current Medicinal Chemistry “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors
Current Pharmaceutical Design Anticancer Potential of Aguerin B, a Sesquiterpene Lactone Isolated from <i>Centaurea behen</i> in Metastatic Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Skeletal Muscle Cell Behavior After Physical Agent Treatments
Current Pharmaceutical Design Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Possible Neuroprotective Strategies in ALS
Current Neuropharmacology β-Galactosylated Alkyl-oligoamine Derivatives of Polyethylenimine Enhanced pDNA Delivery into Hepatic Cells with Reduced Toxicity
Current Nanoscience